ONCOLYTICS BIOTECH INC — Form 8-K
Filed July 8, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 18/100
What the filing says
Ernst & Young LLP (Calgary) issued a letter dated July 7, 2026 regarding Oncolytics Biotech's Form 8-K Item 4.01 filing. The auditor explicitly agreed with statements in the second, third, and fifth paragraphs of Item 4.01 but stated they had no basis to agree or disagree with other statements. The specific content of Item 4.01 is not provided in this exhibit, so the nature of the underlying disclosure cannot be determined from this text alone.
Why this rating
Routine auditor agreement letter; procedural compliance. No financial impact, counterparties, amounts, or business change disclosed. Standard SEC filing administrative matter.
Extracted items
See more from July 8, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.